PTC shares soar after SMA drug data impresses marketAfter failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on Share XPTC shares soar after SMA drug data impresses markethttps://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/
Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chancesBiogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a Share XBiogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chanceshttps://pharmaphorum.com/news/biogen-sees-spinraza-slow-q3/
